Early Predictors of Prognostic Course in Patients With COVID-19 in Critical or Semi-intensive Area.
Launched by UNIVERSITY OF TURIN, ITALY · May 3, 2021
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • hospitalized patients with clinical signs and symptoms of COVID-19, confirmed by nasopharyngeal swab RT-PCR of airways positive for SARS-CoV-2
- • age \> 18 years
- • Hospitalization in the departments of the hospitals involved
- Exclusion Criteria:
- • none
About University Of Turin, Italy
The University of Turin, located in Italy, is a prestigious academic institution renowned for its commitment to research and innovation in the medical field. As a clinical trial sponsor, the university leverages its extensive expertise and resources to advance scientific knowledge and improve patient outcomes. Collaborating with a network of healthcare professionals and researchers, the University of Turin conducts rigorous clinical trials that adhere to the highest ethical and regulatory standards. Its focus on translational research ensures that findings contribute to the development of effective therapies and healthcare solutions, enhancing the overall well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Torino, , Italy
Patients applied
Trial Officials
Luca Brazzi, Professor
Study Chair
University of Torino
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials